Tandem Diabetes Care — Third Quarter 2026 Earnings Summary

Tandem Diabetes Care reported third-quarter 2026 worldwide sales of $283.7 million, representing a 14% increase from the prior year period. The company achieved a gross margin of 57% and reduced its operating loss to $2.4 million, a significant improvement from the $22.9 million loss recorded in the same quarter of 2025. Pump shipments reached approximately 33,000 units globally, with nearly 23,000 units shipped in the United States. For the full year 2026, the company reaffirmed its sales guidance of $1.065 billion to $1.085 billion and an adjusted EBITDA margin of 5% to 6%.